Another issue that seems to be worth addressing is whether germline benign or likely benign variants of the RET protooncogene impact the clinical outcome of sporadic MTC patients depending on somatic driver mutations in the tumour tissue, i.e., in RET and particularly RAS family protooncogenes, present in up to 80% of such cases [1]. The gene discussed is RET; the disease is neoplasm.